Vera Therapeutics Q2 net loss $33.7M; gets FDA Breakthrough Therapy Designation for atacicept in IgAN

Vera Therapeutics, Inc.

2024-Q2 EPS reported -$1.17

Net loss $33.7M ($0.62/diluted share) vs $20.2M ($0.46) in Q2 2023; cash $384.4M sufficient through approval and US launch.
FDA granted Breakthrough Therapy Designation for atacicept in IgA Nephropathy (IgAN).
Phase 2b ORIGIN data: atacicept stabilized kidney function through 72 weeks, reduced hematuria; 96-week data expected Q4 2024.
Phase 3 ORIGIN 3 enrollment on track to complete Q3 2024; topline data expected Q2 2025.
Appointed David L. Johnson COO, Amit Sharma EVP Medical Affairs; Christy J. Oliger to board.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.